HOME>News & Media
Innovation today, healthier tomorrows

 

For media inquiries, contact us at 508-357-7740 or email at corpcomm@sunovion.com.

2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

 Date  Title
9/20/16 Sunovion Announces Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD
9/16/16 Sunovion to Present Data on Latuda® (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress
8/31/16 Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
8/18/16 Sunovion Hands On! Annual Community Service Program Contributes More Than 20,000 Employee Volunteer Hours Over Five Years To Support Youth Organizations And Community Relief Efforts
8/8/16 Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda® (lurasidone HCl) in the Treatment of Schizophrenia
7/29/16 Sunovion Submits New Drug Application for SUN-101/eFlow® to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
7/22/16 Sunovion Announces Results of Phase 3 Long-Term Safety Study Showing SUN-101/eFlow® (glycopyrrolate) Was Well-Tolerated in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
5/23/16 Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda® (lurasidone HCl) in the Treatment of Bipolar Depression
5/16/16 Sunovion Announces Health Outcomes Data on Exacerbation-Related Hospitalizations that Support the Use of Brovana® (arfomoterol tartrate) Inhalation Solution in People with Moderate-to-Severe COPD at the 2016 ATS Conference
5/15/16 American Thoracic Society (ATS) and Sunovion Release Landmark Survey of Pulmonologists’ Attitudes and Practices with Inhalation Devices for COPD at the ATS 2016 International Conference
5/12/16 Sunovion to Present Data on Latuda® (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association
5/4/16 Sunovion Presents New Health Outcomes Data Supporting Brovana® (arformoterol tartrate) Inhalation Solution in People with Moderate-to-Severe COPD at the 2016 American Thoracic Society (ATS) International Conference
4/27/16 Sunovion Pharmaceuticals Inc. Announces Positive Results from Two Phase 3 Clinical Studies Evaluating SUN-101/eFlow® (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
4/15/16 Sunovion Announces Results of Health Outcomes Analyses Supporting the Use of Aptiom® (eslicarbazepine acetate) in People with Partial-Onset Seizures at the 68th American Academy of Neurology (AAN) Annual Meeting
4/6/16 Sunovion to Present Data Analyses Supporting Use of Aptiom® (eslicarbazepine acetate) at the 68th American Academy of Neurology (AAN) Annual Meeting
3/7/16 New Health Outcomes Data Reinforce Role of Device Selection and Peak Inspiratory Flow Rate in Treatment of COPD Patients
1/25/16 Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline